Display options
Cite
Hagiya A, Vaidya P, Khedro T, et al. Bone Marrow Features in Patients With Acute Myeloid Leukemia Treated With Novel Targeted Isocitrate Dehydrogenase 1/2 Inhibitors. World J Oncol. 2019;10(6):226-230doi: 10.14740/wjon1231.
Hagiya, A., Vaidya, P., Khedro, T., Yaghmour, B., Siddiqi, I., & Yaghmour, G. (2019). Bone Marrow Features in Patients With Acute Myeloid Leukemia Treated With Novel Targeted Isocitrate Dehydrogenase 1/2 Inhibitors. World journal of oncology, 10(6), 226-230. https://doi.org/10.14740/wjon1231
Hagiya, Ashley, et al. "Bone Marrow Features in Patients With Acute Myeloid Leukemia Treated With Novel Targeted Isocitrate Dehydrogenase 1/2 Inhibitors." World journal of oncology vol. 10,6 (2019): 226-230. doi: https://doi.org/10.14740/wjon1231
Hagiya A, Vaidya P, Khedro T, Yaghmour B, Siddiqi I, Yaghmour G. Bone Marrow Features in Patients With Acute Myeloid Leukemia Treated With Novel Targeted Isocitrate Dehydrogenase 1/2 Inhibitors. World J Oncol. 2019 Dec;10(6):226-230. doi: 10.14740/wjon1231. Epub 2019 Dec 16. PMID: 31921378; PMCID: PMC6940036.
Copy Download .nbib Format: NLM
Share it on

World J Oncol. 2019 Dec;10(6):226-230. doi: 10.14740/wjon1231. Epub 2019 Dec 16.

Bone Marrow Features in Patients With Acute Myeloid Leukemia Treated With Novel Targeted Isocitrate Dehydrogenase 1/2 Inhibitors.

World journal of oncology

Ashley Hagiya, Poorva Vaidya, Tarek Khedro, Bassam Yaghmour, Imran Siddiqi, George Yaghmour

Affiliations

  1. Department of Pathology, Keck School of Medicine of University of Southern California, Los Angeles, CA 90033, USA.
  2. Internal Medicine, Keck School of Medicine of University of Southern California, Los Angeles, CA 90033, USA.
  3. Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Keck School of Medicine of University of Southern California, Los Angeles, CA 90033, USA.
  4. Pulmonary Critical Care, Keck School of Medicine of University of Southern California, Los Angeles, CA 90033, USA.

PMID: 31921378 PMCID: PMC6940036 DOI: 10.14740/wjon1231

Abstract

This case report aimed to review the bone marrow features of patients with acute myeloid leukemia (AML) treated with isocitrate dehydrogenase 1/2 (

Copyright 2019, Hagiya et al.

Keywords: Acute myeloid leukemia; Bone marrow microenvironment; Isocitrate dehydrogenase inhibitors

Conflict of interest statement

The authors do not have any conflict of interest.

References

  1. Blood. 2010 Sep 23;116(12):2122-6 - PubMed
  2. Am J Hematol. 2015 Jun;90(6):504-10 - PubMed
  3. Curr Hematol Malig Rep. 2017 Dec;12(6):537-546 - PubMed
  4. Blood. 2017 Aug 10;130(6):722-731 - PubMed
  5. Haematologica. 2018 Sep;103(9):e404-e407 - PubMed
  6. Blood. 2019 Feb 14;133(7):676-687 - PubMed
  7. Blood. 2017 Aug 10;130(6):732-741 - PubMed
  8. Hum Pathol. 2012 Oct;43(10):1541-51 - PubMed
  9. N Engl J Med. 2018 Jun 21;378(25):2386-2398 - PubMed

Publication Types